The effect of a comprehensive lifestyle intervention on cardiovascular risk factors in pharmacologically treated patients with stable cardiovascular disease compared to usual care: a randomised controlled trial

Table 2 Prescribed medication at baseline and at 6-months follow-up for those who remained in the trial (n = 146)

Drug class	Baseline data for those who remained in the trial		Data at 6-months follow-up
Drug class	Intervention n = 59	Control n = 60	Intervention n = 59	Control n = 60
Antithrombotica
Acetylsalicylic acid (aspirin)	47 (79.7%)	54 (90.0%)	49 (83.1%)	52 (86.7%)
Blood pressure-lowering medication
Angiotensin-converting enzyme (ACE inhibitors)	24 (40.7%)	21 (35.0%)	27 (45.8%)	20 (33.3%)
β-blocker	34 (57.6%)	38 (63.3%)	33 (55.9%)	40 (66.7%)
Calcium-channel blocker	12 (20.3%)	19 (31.7%)	16 (27.1%)	18 (30.0%)
Diuretica	12 (20.3%)	12 (20.0%)	12 (20.3%)	10 (16.7%)
Lipid-lowering medication
Statins	51 (86.4%)	49 (81.7%)	53 (89.8%)	54 (90.0%)
Blood glucose-lowering medication ^a
Biguanides	9 (15.3%)	7 (11.7%)	10 (16.9%)	7 (11.7%)

n=number of patients; %, percentage of patients who remained in the study; ^adata based on diabetic patients at baseline and at 6-months follow-up.

ISSN: 1471-2261